ReviewACS omega2025
Plant Defense Peptides: Exploring the Structure-Function Correlation for Potential Applications in Drug Design and Therapeutics.
Review in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Cysteine-Rich Peptides in Food Systems: Structure, Sources, Functional Properties, Potential Applications, and Future Perspectives.Probiotics and antimicrobial proteins · 2026Review
- Selective α-Amylase Inhibition by Plant Defensins: Structural Determinants, Engineering Strategies, and Translational Prospects.Probiotics and antimicrobial proteins · 2026Review
- FungiGuard: identification of plant antifungal peptides with artificial intelligence.Genome biology · 2026Article
- Discovery, Isolation, and Bactericidal Activity of a Cyclotide fromJournal of natural products · 2026Article
- Review
- A Comprehensive Overview of Antimicrobial Peptides: Broad-Spectrum Activity, Computational Approaches, and Applications.Antibiotics (Basel, Switzerland) · 2025Review
- Thionins: potential use in plant defense against pathogens.Plant molecular biology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Defense peptides are part of plants' innate immune system and show widespread occurrence across the plant kingdom. Most of them belong to the category of antimicrobial peptides (AMPs) and act as strong chemical weapons against the biotic stresses that plants encounter. Plant AMP families exhibit remarkably conserved topology, being cysteine-rich with a conserved number of disulfide bridges stabilizing their three-dimensional structure, cationic in nature, and having hydrophobic surfaces. However, specific structural properties like amino acid sequence, distribution of charged and hydrophobic residues, secondary conformations, and polar angle play significant roles in fine-tuning their natural functions and their interactions with biological membranes. Considering their vital role in plant defense and strong structure-function relationships, these peptides have been explored for huge potential in human health and therapeutics. Owing to the structural flexibilities, cyclotides are considered promising scaffolds as drug design frameworks toward various targets and applications in therapeutics. To elaborate on this idea, we discuss the functional heterogeneity within the much-conserved cyclotide subfamilies. We discuss Möbius, bracelet, and trypsin inhibitor family cyclotides with respect to their membrane binding affinities pivoting on the surface charge and hydrophobicity. The decrease of peptide hydrophobicity and increase of electrostatic surface are associated with more specific antimicrobial selectivity and less toxicity to eukaryotic cells, widening their range of intracellular targets. We also discuss the application of AMPs in therapeutics and recent advances in the delivery of AMPs using nanosystems as vehicles.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.